

SUPPLEMENTAL MATERIAL

Lu et al., <http://www.jem.org/cgi/content/full/jem.20130208/DC1>




Figure S1. Validation of the Blimp-1 antibody. Western blots were performed with the Blimp-1 antisera as follows. (A) 5 µg of whole cell lysates from EL4 cells transduced with GFP (lane 1)– and Blimp-1 (lane 2)–expressing adenovirus vectors. (B) 10 µg of nuclear lysates was prepared from splenic B cells from WT (lane 1) and Blimp-1^{f/f};Tg^{Cre-CD19} (Shapiro-Shelef et al., 2003; lane 2) mice incubated with LPS, IL-2, and IL-5, as previously described (Yoon and Boss, 2010; Yoon et al., 2012), for 3 d to induce plasma cell differentiation and expression of Blimp-1. All lysates were separated on SDS-PAGE and processed for Western blotting according to standard protocols. Western blots were stained with the anti-Blimp-1 antisera (Rockland Immunochemicals, Inc.) at a dilution of 1:1,000. Blots were stripped and reprobed with anti β-actin (Santa Cruz Biotechnology, Inc.) at 1:1,000. The Blimp-1 bands were labeled with an arrow.

Table S1. PCR primers

Primer name	Primer sequence (5'-3')
Cloning and mutagenesis primers	
M1 forward	CCAGGGCTGAGAGAGACTCGTAGGGCCAGACTCTTGC
M1 reserves	GACAAGAGCTGGCCCTAGACGAAGTCTCTCAGCCCTGG
M2 forward	GCTCTGCTGCCCTGCATCCGATTCTTCCCCTGAGAAAAACC
M2 reserves	GGTTTTCTCAGGGGAAGAAATCGGATGCAGGGCAGCAGAGC
M3 forward	GAAAGGACCTCTGCCTATCGATTCTTCCCCTTGCTG
M3 reserves	CAGCAGAAGGGAAAAGAACATGGATAGGCAGAGGCTTTC
ΔSite2 forward-1	GTCAAGCTGGCAGTGTGCGCTTCAGTAG
ΔSite2 reverse-1	TAGGTTTCTCAGGCAGCAGAGCTAGCAAACCTAAG
ΔSite2 forward-2	TTGCTAGCTCTGCTGCCTGAGAAAACCTAACACCCAG
ΔSite2 reverse-2	TGACTCGAGGAGGACTCTGTCCATGAGCC
1.1 kb NFATc1 P forward	GTCAAGATCTCTGAAACTTGAGCGCTGGGTG
1.1 kb NFATc1 P reverse	GAACCTTCAAAACCTGCAGGGATGC
1.9 kb NFATc1 P forward	GCATCCCTGCAGGTTGAAGGTT
1.9 kb NFATc1 P reverse	CTGAAGCTTAGTCCGACCTCTCCTTGCCGACAC
Real-time RT-PCR primers	
PD-1 forward	CGTCCCTCAGTCAGAGAGGAG
PD-1 reverse	GTCCTAGAAGTGCCAACAA
NFATc1 forward	GCTGGTCTCCGAGTTCACATCC
NFATc1 reverse	GCTGTCTGCTGCTGCTCTCC
Blimp-1 forward	ATGGAGGACGCTGATATGAC
Blimp-1 reverse	CCTTAACCTACACGCCAATAAC
Blimp-1 KO forward	TTCAGTGCCAGACCTGCAACAAAG
Blimp-1 KO reverse	TCCAGAAATGCAATCGAAGGGTGGGT
Bcl6 forward	CACACTCGAATTCACTCTG
Bcl6 reverse	TATTGCACCTTGGTGTGG
Cre forward	GCAGAACCTGAAGATGTTCGC
Cre reverse	CATTGCTGTCACTTGGTCGTG
18S forward	GTAACCCGTTGAACCCCAT
18S reverse	CCATCCAATCGGTAGAGCCG
DNase I hypersensitivity assay primers	
CR-C forward	CGACTTGTGTCATGCATAGTACC
CR-C reverse	GAGGTCTTCACTCTCCACG
Control site forward	CCAGCTATCCCACATGCTCCC
Control site reverse	GGACTGAGGAAAGTTGACTGG
Insensitive site forward	TAGCACATAACAGCGGTAGATTAC
Insensitive site reverse	CCCAAGTTGAGACAAGCAGAC
ChIP assay primers	CTGACTAGCTGCTTGCCTC
Blimp-1 Site1 forward	CATAGGTACCAAGCCAGGC
Blimp-1 Site1 reverse	TTCAAGATGCTGGATCTGCTG
Blimp-1 Site2 forward	GGACTGAGGAAAGTTGACTGG
Blimp-1 Site2 reverse	CGTGGAGAGTGAAAGGACCTC
Blimp-1 Site3 forward	ATTGCATGTGTTGGCTATTG
Blimp-1 Site3 reverse	GGCAGTGTGCGCTTCAGTAGC
CR-B forward	CCACCTCTAGTTGCCTGTTCTC
CR-B reverse	CCTCACCTCTGCTTGTCTCTC
CR-C forward	GTGAGACCCACACATCTATTGC
CR-C reverse	ATCCCCATCCATACCTGCTCC
Control site forward	ATCGAGCTGTGCTGATGGACAC
Control site reverse	CCTCACCTCTGCTTGTCTCTC
NFATc1 forward	GTGAGACCCACACATCTATTGC
NFATc1 reverse	CTGACTAGCTGCTTGCCTC